Brief: Spago Nanomedical Updates On Clinical Phase IIa Study Spagopix-02
June 28 (Reuters) - Spago Nanomedical AB (publ) SPAGO.ST :
* UPDATES ON THE CLINICAL PHASE IIA STUDY SPAGOPIX-02
* PRELIMINARY ANALYSIS OF DATA FROM PHASE IIA CLINICAL STUDY SPAGOPIX-02 SHOWS THAT SN132D
HAS A
GOOD SAFETY PROFILE IN PATIENTS WITH ENDOMETRIOSIS.
Source text for Eikon: ID:nMFN9XJcbm
Further company coverage: SPAGO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Spago Nanomedical AB (publ)
See all newsBrief: Spago Nanomedical Announces Outcome Of Rights Issue
Brief: Spago Nanomedical Resolves On Rights Issue Of About SEK 16 Million
Sweden's Spago Nanomedical Q1 loss narrows
Brief: Spago Nanomedical Q1 Sales SEK 22 Thousand
Brief: Spago Nanomedical Says Tumorad-01 Study Meets Primary Endpoint Of Maximum Tolerated Dose